Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21ClFN3O3 |
Molecular Weight | 393.84 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H]1CCCCN(C1)C2=C(F)C=C3C(=O)C(=CN(C4CC4)C3=C2Cl)C(O)=O
InChI
InChIKey=QFFGVLORLPOAEC-SNVBAGLBSA-N
InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1
Besifloxacin (INN/USAN) is a fourth-generation fluoroquinolone antibiotic. The marketed compound is Besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 for ophthalmic use to InSite Vision Incorporated in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003. Besifloxacin is indicated in the treatment of bacterial conjunctivitis caused by sensitive germs, as well as in the prevention of infectious complications in patients undergoing laser therapy for the treatment of cataracts. Besifloxacin inhibits bacterial DNA gyrase and topoisomerase IV and has a broad spectrum of bactericidal activity against strains commonly isolated from patients with bacterial conjunctivitis. In addition, some exploratory in vitro data suggest that Besifloxacin inhibits cytokine formation in human corneal epithelial cells and monocytes, but the relevance of this finding to therapeutic efficacy is unknown.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363076 |
|||
Target ID: CHEMBL2311224 |
|||
Target ID: CHEMBL2363076 |
|||
Target ID: CHEMBL2311224 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BESIVANCE Approved UseINDICATIONS AND USAGE. Besivance® (besifloxacin ophthalmic suspension) 0.6%, is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans *, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae Moraxella catarrhalis*, Pseudomonas aeruginosa *, Moraxella lacunata*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections. Launch Date1.24338242E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
610 μg/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19492955/ |
1 drop 4 times / day multiple, oral dose: 1 drop route of administration: Oral experiment type: MULTIPLE co-administered: |
BESIFLOXACIN cornea | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.37 ng/mL |
1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered: |
BESIFLOXACIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
56.4525 ng/ml Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01296191 |
1 drop 4 times / day multiple, ocular dose: 1 drop route of administration: ocular experiment type: multiple co-administered: |
BESIFLOXACIN aqueous humor | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.232 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19492955/ |
1 drop 4 times / day multiple, oral dose: 1 drop route of administration: Oral experiment type: MULTIPLE co-administered: |
BESIFLOXACIN cornea | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19492955/ |
1 drop 4 times / day multiple, oral dose: 1 drop route of administration: Oral experiment type: MULTIPLE co-administered: |
BESIFLOXACIN cornea | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7 h |
1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered: |
BESIFLOXACIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 drop 3 times / day multiple, topical Recommended Dose: 1 drop, 3 times / day Route: topical Route: multiple Dose: 1 drop, 3 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Bacterial conjunctivitis Sources: Page: p.3 |
Disc. AE: Bacterial resistance... AEs leading to discontinuation/dose reduction: Bacterial resistance Sources: Page: p.3 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bacterial resistance | Disc. AE | 1 drop 3 times / day multiple, topical Recommended Dose: 1 drop, 3 times / day Route: topical Route: multiple Dose: 1 drop, 3 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Bacterial conjunctivitis Sources: Page: p.3 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022308s000_ClinPharmR.pdf#PAGE=26 Page: 26.0 |
unlikely | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022308s000_ClinPharmR.pdf#PAGE=26 Page: 26.0 |
unlikely |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022308s000_ClinPharmR.pdf#PAGE=26 Page: 26.0 |
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 14.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. | 2007 Jun |
|
Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. | 2008 Jan |
|
Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry. | 2008 May 1 |
|
Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. | 2008 Nov |
|
Besifloxacin ophthalmic suspension for bacterial conjunctivitis. | 2009 Aug |
|
Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. | 2009 Aug |
|
New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine. | 2009 Jul-Aug |
|
Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. | 2009 Mar |
|
Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. | 2009 Mar |
|
Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. | 2009 May |
|
Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. | 2009 Oct |
|
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. | 2009 Oct |
|
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. | 2009 Sep |
|
Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. | 2010 |
|
Besifloxacin ophthalmic suspension 0.6%. | 2010 |
|
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. | 2010 Apr |
|
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. | 2010 Apr 1 |
|
Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections. | 2010 Dec |
|
New Drugs2010, PART 1. | 2010 Feb |
|
Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. | 2010 Jul |
|
Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. | 2010 Jun |
|
Comparative effects of besifloxacin and other fluoroquinolones on corneal reepithelialization in the rabbit. | 2010 Jun |
|
Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. | 2010 Mar |
|
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits. | 2010 Oct |
|
An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin. | 2010 Oct |
|
Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. | 2010 Sep |
|
Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. | 2012 Jun |
Patents
Sample Use Guides
Instill one drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01AE08
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
||
|
WHO-ATC |
S01AE08
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
||
|
WHO-ATC |
S01AX23
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
||
|
NDF-RT |
N0000175937
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
||
|
NDF-RT |
N0000007606
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Besifloxacin
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
BFE2NBZ7NX
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
DB06771
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
8958
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
10178705
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
100000126378
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
819911
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB33064
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
4111
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
C83553
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
CHEMBL1201760
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
DTXSID00161706
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
141388-76-3
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
BFE2NBZ7NX
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
C522124
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | |||
|
m2448
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY | Merck Index | ||
|
Besifloxacin
Created by
admin on Fri Dec 15 16:33:19 UTC 2023 , Edited by admin on Fri Dec 15 16:33:19 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)